MX2021000965A - Composiciones que comprenden polirribonucleotidos circulares y usos de estas. - Google Patents

Composiciones que comprenden polirribonucleotidos circulares y usos de estas.

Info

Publication number
MX2021000965A
MX2021000965A MX2021000965A MX2021000965A MX2021000965A MX 2021000965 A MX2021000965 A MX 2021000965A MX 2021000965 A MX2021000965 A MX 2021000965A MX 2021000965 A MX2021000965 A MX 2021000965A MX 2021000965 A MX2021000965 A MX 2021000965A
Authority
MX
Mexico
Prior art keywords
compositions
circular polyribonucleotides
polyribonucleotides
circular
preparations
Prior art date
Application number
MX2021000965A
Other languages
English (en)
Inventor
Avak Kahvejian
Nicholas Mccartney Plugis
Catherine Cifuentes-Rojas
Ki Young Paek
Boer Alexandra Sophie De
Morag Helen Stewart
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MX2021000965A publication Critical patent/MX2021000965A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta presente invención se refiere en general a composiciones y preparados farmacéuticos de polirribonucleótidos circulares, y a usos de estos.
MX2021000965A 2018-07-24 2019-07-24 Composiciones que comprenden polirribonucleotidos circulares y usos de estas. MX2021000965A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862702714P 2018-07-24 2018-07-24
US201962823569P 2019-03-25 2019-03-25
US201962863670P 2019-06-19 2019-06-19
PCT/US2019/043272 WO2020023655A1 (en) 2018-07-24 2019-07-24 Compositions comprising circular polyribonucleotides and uses thereof

Publications (1)

Publication Number Publication Date
MX2021000965A true MX2021000965A (es) 2021-06-15

Family

ID=69182387

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000965A MX2021000965A (es) 2018-07-24 2019-07-24 Composiciones que comprenden polirribonucleotidos circulares y usos de estas.

Country Status (12)

Country Link
US (1) US20210292761A1 (es)
EP (1) EP3827084A4 (es)
JP (1) JP2021531022A (es)
KR (1) KR20210039401A (es)
CN (1) CN112567038A (es)
AU (1) AU2019312269A1 (es)
BR (1) BR112021001343A2 (es)
CA (1) CA3107683A1 (es)
IL (1) IL280354A (es)
MX (1) MX2021000965A (es)
SG (1) SG11202100750XA (es)
WO (1) WO2020023655A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017280943B2 (en) 2016-06-20 2023-05-18 Emory University Circular RNAs and their use in immunomodulation
EP3589751A4 (en) 2017-03-03 2021-11-17 The Regents of The University of California RNA TARGETING OF MUTATIONS VIA SUPPRESSOR RNA AND DEAMINASES
JP2021508490A (ja) 2017-12-15 2021-03-11 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを含む組成物及びその使用
US20230072532A1 (en) * 2019-03-25 2023-03-09 Flagship Pioneering Innovations Vi, Llc Compositions comprising modified circular polyribonucleotides and uses thereof
WO2021113270A1 (en) 2019-12-02 2021-06-10 Shape Therapeutics Inc. Therapeutic editing
EP4096682A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Compositions for translation and methods of use thereof
CN111500681A (zh) * 2020-03-20 2020-08-07 青岛大学 用于检测piRNA与mRNA结合的可视化方法及其应用
WO2021263124A2 (en) 2020-06-25 2021-12-30 The Board Of Trustees Of The Leland Stanford Junior University Genetic elements driving circular rna translation and methods of use
EP4176047A1 (en) * 2020-07-01 2023-05-10 Elevatebio Technologies, Inc Compositions and methods for cellular reprogramming using circular rna
CN113249811B (zh) * 2021-05-13 2022-11-08 太原理工大学 一种中空纳米纤维内部固定化生物酶的制备方法
JP2024523054A (ja) 2021-05-18 2024-06-26 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを濃縮する方法
KR20240035752A (ko) 2021-05-18 2024-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 원형 폴리리보뉴클레오티드의 농축 방법
EP4347830A2 (en) * 2021-06-02 2024-04-10 Beam Therapeutics Inc. Circular guide rnas for crispr/cas editing systems
CN113264842B (zh) 2021-07-21 2022-03-01 苏州科锐迈德生物医药科技有限公司 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
AU2022318881A1 (en) 2021-07-27 2024-02-08 Flagship Pioneering Innovations Vi, Llc Devices, systems and methods for processing
CN114591986A (zh) * 2021-07-29 2022-06-07 苏州科锐迈德生物医药科技有限公司 环状rna分子及其在目标蛋白的靶向降解中的应用
CN118510896A (zh) 2021-12-17 2024-08-16 旗舰创业创新六公司 用于在变性条件下富集环状rna的方法
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR604101A0 (en) * 2001-06-29 2001-07-26 Unisearch Limited Aptamers
CA2617561A1 (en) * 2005-08-01 2007-02-08 Purdue Research Foundation Multivalent rna nanoparticles for delivery of active agents to a cell
DK2800811T3 (en) * 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
CA3026646A1 (en) * 2016-06-07 2017-12-14 Cepheid Thermostable polymerase inhibitor compositions and methods
US20220305128A1 (en) * 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof

Also Published As

Publication number Publication date
WO2020023655A1 (en) 2020-01-30
JP2021531022A (ja) 2021-11-18
KR20210039401A (ko) 2021-04-09
EP3827084A4 (en) 2023-03-15
BR112021001343A2 (pt) 2021-05-04
EP3827084A1 (en) 2021-06-02
IL280354A (en) 2021-03-25
AU2019312269A1 (en) 2021-03-04
US20210292761A1 (en) 2021-09-23
SG11202100750XA (en) 2021-02-25
CA3107683A1 (en) 2020-01-30
CN112567038A (zh) 2021-03-26

Similar Documents

Publication Publication Date Title
MX2020006150A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
MX2021000965A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de estas.
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
WO2020198403A3 (en) Compositions comprising modified circular polyribonucleotides and uses thereof
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
MX2023010042A (es) Polinucleotidos moduladores.
MX2019001313A (es) Composiciones farmaceuticas.
MX2019012434A (es) Agentes inductores de apoptosis.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
MX2020001885A (es) Formulaciones de daptomicina.
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2021006977A (es) Anellosomas y metodos de uso.
EA201792262A1 (ru) Пироглутамат вортиоксетина
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
IN2014CH00840A (es)
WO2018237010A3 (en) VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
MX2020005231A (es) Metodos de uso y composiciones que contienen dulaglutida.